A comparison of medicines used for overactive bladder (fesoterodine vs mirabegron vs solifenacin)
Phase 4
- Conditions
- Health Condition 1: N328- Other specified disorders of bladder
- Registration Number
- CTRI/2024/02/063069
- Lead Sponsor
- VYOMA DESAI
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All cases of overactive bladder undergoing treatment at Dr. PSIMS and RF hospital
Exclusion Criteria
Patients not willing to participate in the study
Patients lost to follow up
Patients less than 18 years of age
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in OABSS scoreTimepoint: 1 month
- Secondary Outcome Measures
Name Time Method Significant side effectsTimepoint: 15 days